Eduardo Borges de Melo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eduardo Borges de Melo has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- João Paulo Ataide Martins
Department of Chemistry, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil
6 shared publications - Aline Thais Bruni
Departamento de Química. Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto. Universidade de São Paulo (DQ/FFCLRP/USP), Avenida Bandeirantes, 3900, Bairro Monte Alegre, Ribeirão Preto - SP, CEP 14040-901, Brazil
3 shared publications Adriana Santos Costa
Theoretical Medicinal and Environmental Chemistry Laboratory (LQMAT), Department of Pharmacy, Western Paraná State University (UNIOESTE), Cascavel, Paraná, Brazil
2 shared publications- Fernanda Stumpf Tonin
Pharmacy and Pharmaceutical Technology Department, Social and Legal Pharmacy Section, University of Granada, Granada, Spain
2 shared publications Luana Janaína de Campos
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, USA
2 shared publications- Luana Janaína de Campos
Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA
2 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by Springer Nature in Chemical Papers
- Vol. 80 (6) , 6727-6744
Multivariate analysis about the influence of solubility and partition molecular descriptors on LogKoc for substituted diphenyl ethers
- 2 April 2026
- Published by Springer Nature in Chemical Papers
- Vol. 80 (6) , 6727-6744
Open AccessMultivariate analysis about the influence of solubility and partition molecular descriptors on LogKoc for substituted diphenyl ethers
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Hybrid 2D/3D-QSAR Study of Methylamine Derivatives as Dopamine Transporter Inhibitors
Compounds that inhibit the dopamine transporter (DAT) protein hold significant therapeutic potential for the treatment of various neurological disorders, including Parkinson’s disease and substance use disorders. In this context, an extensive quantitative structure-activity relationship (QSAR) study was conducted using 36 methylamine derivatives. Three modeling approaches were applied: a 2D-QSAR model based on classical descriptors, a 3D-QSAR model using molecular interaction field (MIF) descriptors, and a hybrid model combining the most relevant 2D and 3D descriptors. All models underwent the same statistical validation procedures. Although each model demonstrated high quality, the hybrid approach proved slightly superior. Furthermore, both the 2D-QSAR and MIF descriptors were found to correlate with the mechanism of DAT inhibition. These findings highlight that integrating complementary molecular information encoded in descriptors of different physicochemical origins can improve the predictive accuracy and robustness of QSAR models. The final model has the potential to serve as a tool to guide the synthesis and virtual screening of novel DAT inhibitors. It shows promising statistical performance and may assist preliminary virtual screening efforts.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Hybrid 2D/3D-QSAR Study of Methylamine Derivatives as Dopamine Transporter Inhibitors
Compounds that inhibit the dopamine transporter (DAT) protein hold significant therapeutic potential for the treatment of various neurological disorders, including Parkinson’s disease and substance use disorders. In this context, an extensive quantitative structure-activity relationship (QSAR) study was conducted using 36 methylamine derivatives. Three modeling approaches were applied: a 2D-QSAR model based on classical descriptors, a 3D-QSAR model using molecular interaction field (MIF) descriptors, and a hybrid model combining the most relevant 2D and 3D descriptors. All models underwent the same statistical validation procedures. Although each model demonstrated high quality, the hybrid approach proved slightly superior. Furthermore, both the 2D-QSAR and MIF descriptors were found to correlate with the mechanism of DAT inhibition. These findings highlight that integrating complementary molecular information encoded in descriptors of different physicochemical origins can improve the predictive accuracy and robustness of QSAR models. The final model has the potential to serve as a tool to guide the synthesis and virtual screening of novel DAT inhibitors. It shows promising statistical performance and may assist preliminary virtual screening efforts.
- Open Access
- 12 December 2024
- Published by MDPI AG in Chemistry Proceedings
- Vol. 16 (1) , 35
Investigating SAR Insights into Royleanones for P-gp Modulation
Multidrug resistance (MDR) presents a significant challenge in modern pharmacotherapy, greatly diminishing the effectiveness of chemotherapeutic agents. A primary mechanism contributing to MDR is the overexpression of P-glycoprotein (P-gp), also known as MDR1, encoded by the ABCB1 gene, which hampers the success of cancer treatments. Plants from the Plectranthus genus (Lamiaceae) have been traditionally acknowledged for their diverse therapeutic applications. The principal diterpene from Plectranthus grandidentatus Gürke, 7α-acetoxy-6β-hydroxyroyleanone (Roy), has demonstrated anticancer properties against various cancer cell lines. Previously synthesized ester derivatives of Roy have shown improved binding affinity to P-gp. This study employs previously acquired in vitro data on the P-gp activity of Roy derivatives to develop a ligand-based pharmacophore model, highlighting critical features necessary for P-gp modulation. Utilizing these data, we predict the potential of five novel ester derivatives of Roy to modulate P-gp in vitro against resistant NCI-H460 cells. In silico structure–activity relationship (SAR) studies were conducted on 17 previously synthesized royleanone derivatives. A binary classification model was constructed, distinguishing inactive from active compounds, generating 11,016 molecular interaction field (MIF) descriptors from structures optimized at the DFT level. After variable reduction and selection, 12 descriptors were chosen, resulting in a model with two latent variables (LV), using only 34.14% of the encoded information for calibration (LV1: 26.82%; LV2: 7.32%). The activity prediction of new derivatives suggested that four of them have a high likelihood of activity, which will be validated in future in vitro biological assays.
- 12 December 2024
- Published by MDPI AG in Chemistry Proceedings
- Vol. 16 (1) , 35
Open AccessInvestigating SAR Insights into Royleanones for P-gp Modulation
Multidrug resistance (MDR) presents a significant challenge in modern pharmacotherapy, greatly diminishing the effectiveness of chemotherapeutic agents. A primary mechanism contributing to MDR is the overexpression of P-glycoprotein (P-gp), also known as MDR1, encoded by the ABCB1 gene, which hampers the success of cancer treatments. Plants from the Plectranthus genus (Lamiaceae) have been traditionally acknowledged for their diverse therapeutic applications. The principal diterpene from Plectranthus grandidentatus Gürke, 7α-acetoxy-6β-hydroxyroyleanone (Roy), has demonstrated anticancer properties against various cancer cell lines. Previously synthesized ester derivatives of Roy have shown improved binding affinity to P-gp. This study employs previously acquired in vitro data on the P-gp activity of Roy derivatives to develop a ligand-based pharmacophore model, highlighting critical features necessary for P-gp modulation. Utilizing these data, we predict the potential of five novel ester derivatives of Roy to modulate P-gp in vitro against resistant NCI-H460 cells. In silico structure–activity relationship (SAR) studies were conducted on 17 previously synthesized royleanone derivatives. A binary classification model was constructed, distinguishing inactive from active compounds, generating 11,016 molecular interaction field (MIF) descriptors from structures optimized at the DFT level. After variable reduction and selection, 12 descriptors were chosen, resulting in a model with two latent variables (LV), using only 34.14% of the encoded information for calibration (LV1: 26.82%; LV2: 7.32%). The activity prediction of new derivatives suggested that four of them have a high likelihood of activity, which will be validated in future in vitro biological assays.
- Open Access
- 22 November 2024
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 92 (4) , 61
Corticosteroids and the Pharmacological Management of Autism—An Integrative Review
Autism spectrum disorder (ASD), or autism, is a lifelong neurodevelopmental condition typically detected during early childhood, for which no specific and efficient pharmacological management is currently available. No drugs have been developed specifically for the pharmacological management of autism. Thus, this approach often relies on various conventional psychotropic medications and, depending on the condition, other medications may also be used. Some studies available in the literature indicate that the adjunctive use of corticosteroids can help improve the quality of life of individuals with autism. Therefore, we conducted an integrative review using four databases, which were PubMed, Scopus, Web of Science, and Google Scholar, focusing on clinical trials and animal model studies involving corticosteroids related to autism. We analyzed the effects of treatment on core and associated autism symptoms, as well as adverse effects. Eight studies were selected and analyzed, seven involving humans and one using an animal model. These studies focused on the drugs pregnenolone (3), prednisolone (3), hydrocortisone (1), and betamethasone (1) in trials either alone or in combination with other medications (such as risperidone). We observed that corticosteroids safely and effectively reduced several symptoms, including stereotypical and social behaviors, hyperactivity, and irritability. Furthermore, no serious adverse effects were observed, although all selected studies were of short duration. Thus, corticosteroids are promising options to be included in the pharmacological management of autism, whether or not in combination with other medications, and further studies are needed to evaluate their long-term effectiveness.
- 22 November 2024
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 92 (4) , 61
Open AccessCorticosteroids and the Pharmacological Management of Autism—An Integrative Review
Autism spectrum disorder (ASD), or autism, is a lifelong neurodevelopmental condition typically detected during early childhood, for which no specific and efficient pharmacological management is currently available. No drugs have been developed specifically for the pharmacological management of autism. Thus, this approach often relies on various conventional psychotropic medications and, depending on the condition, other medications may also be used. Some studies available in the literature indicate that the adjunctive use of corticosteroids can help improve the quality of life of individuals with autism. Therefore, we conducted an integrative review using four databases, which were PubMed, Scopus, Web of Science, and Google Scholar, focusing on clinical trials and animal model studies involving corticosteroids related to autism. We analyzed the effects of treatment on core and associated autism symptoms, as well as adverse effects. Eight studies were selected and analyzed, seven involving humans and one using an animal model. These studies focused on the drugs pregnenolone (3), prednisolone (3), hydrocortisone (1), and betamethasone (1) in trials either alone or in combination with other medications (such as risperidone). We observed that corticosteroids safely and effectively reduced several symptoms, including stereotypical and social behaviors, hyperactivity, and irritability. Furthermore, no serious adverse effects were observed, although all selected studies were of short duration. Thus, corticosteroids are promising options to be included in the pharmacological management of autism, whether or not in combination with other medications, and further studies are needed to evaluate their long-term effectiveness.
- 2 October 2024
- Published by Taylor & Francis in SAR and QSAR in Environmental Research
- Vol. 35 (10) , 877-897
Analysis of oral and inhalation toxicity of per- and polyfluoroalkylated organic compounds in rats and mice using multivariate QSAR
Per- and polyfluoroalkylated organic compounds (PFAs) are versatile compounds extensively used in global industries. However, they are also persistent organic pollutants (POPs). This study aimed to develop new models for assessing oral and inhalation toxicity in rat and mice models. A set of 407 PFAs from the literature was divided into four groups based on the endpoints of interest. The models were constructed using only 2D structure descriptors derived from SMILES strings. The resulting models showed a strong statistical quality for all endpoints. They present an applicability domain (AD) that ensures good reliability, and provided meaningful interpretation, which are partially supported by existing literature. Consequently, these models are valuable for understanding how PFAs exert their toxic effect on mammals and for predicting the risk associated with these significant industrial chemical agents.
- 2 October 2024
- Published by Taylor & Francis in SAR and QSAR in Environmental Research
- Vol. 35 (10) , 877-897
Analysis of oral and inhalation toxicity of per- and polyfluoroalkylated organic compounds in rats and mice using multivariate QSAR
Per- and polyfluoroalkylated organic compounds (PFAs) are versatile compounds extensively used in global industries. However, they are also persistent organic pollutants (POPs). This study aimed to develop new models for assessing oral and inhalation toxicity in rat and mice models. A set of 407 PFAs from the literature was divided into four groups based on the endpoints of interest. The models were constructed using only 2D structure descriptors derived from SMILES strings. The resulting models showed a strong statistical quality for all endpoints. They present an applicability domain (AD) that ensures good reliability, and provided meaningful interpretation, which are partially supported by existing literature. Consequently, these models are valuable for understanding how PFAs exert their toxic effect on mammals and for predicting the risk associated with these significant industrial chemical agents.
- 29 January 2024
- Published by Springer Nature in Structural Chemistry
- Vol. 35 (4) , 1289-1299
A QSAR and similarity search based on 1,2-benzisothiazol-3-ones to identify potential new inhibitors of caspase-3
- 29 January 2024
- Published by Springer Nature in Structural Chemistry
- Vol. 35 (4) , 1289-1299
A QSAR and similarity search based on 1,2-benzisothiazol-3-ones to identify potential new inhibitors of caspase-3
- 6 September 2023
- Published by Springer Nature in Molecular Diversity
- Vol. 28 (5) , 2931-2946
Multivariate QSAR, similarity search and ADMET studies based in a set of methylamine derivatives described as dopamine transporter inhibitors
The dopamine transporter (DAT), responsible for the regulation of dopaminergic neurotransmission, is implicated in the etiology of several neuropsychiatric disorders which, in turn, have contributed to high rates of disability and numerous deaths in recent years, significantly impacting the global health system. Although the research for new drugs for the treatment of neuropsychiatric disorders has evolved in recent years, the availability of DAT-selective drugs that do not generate the same psychostimulant effects observed in drugs of abuse remains scarce. Therefore, we performed a QSAR study based on a dataset of 36 methylamine derivatives described as DAT inhibitors. The model was obtained based only in descriptors derived from 2D structures, and it was validated and generated satisfactory results considering the metrics used for internal and external validation. Subsequently, a virtual screening step also based on 2D similarity was performed, where it was possible to identify a total of 1157 compounds. After a series of reductions of the set using toxicity filters, applicability domain evaluation, and pharmacokinetic properties in silico assessment, seven hit compounds were selected as the most promising to be used, in future studies, as new scaffolds for the development of new DAT inhibitors.
- 6 September 2023
- Published by Springer Nature in Molecular Diversity
- Vol. 28 (5) , 2931-2946
Multivariate QSAR, similarity search and ADMET studies based in a set of methylamine derivatives described as dopamine transporter inhibitors
The dopamine transporter (DAT), responsible for the regulation of dopaminergic neurotransmission, is implicated in the etiology of several neuropsychiatric disorders which, in turn, have contributed to high rates of disability and numerous deaths in recent years, significantly impacting the global health system. Although the research for new drugs for the treatment of neuropsychiatric disorders has evolved in recent years, the availability of DAT-selective drugs that do not generate the same psychostimulant effects observed in drugs of abuse remains scarce. Therefore, we performed a QSAR study based on a dataset of 36 methylamine derivatives described as DAT inhibitors. The model was obtained based only in descriptors derived from 2D structures, and it was validated and generated satisfactory results considering the metrics used for internal and external validation. Subsequently, a virtual screening step also based on 2D similarity was performed, where it was possible to identify a total of 1157 compounds. After a series of reductions of the set using toxicity filters, applicability domain evaluation, and pharmacokinetic properties in silico assessment, seven hit compounds were selected as the most promising to be used, in future studies, as new scaffolds for the development of new DAT inhibitors.
- Open Access
- 19 August 2023
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 32 (1) , 469
Correction: Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies
- 19 August 2023
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 32 (1) , 469
Open AccessCorrection: Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies
- 21 November 2022
- Published by Springer Nature in Molecular Diversity
- Vol. 27 (5) , 2217-2238
Pharmacophore modeling, molecular docking, and molecular dynamics studies to identify new 5-HT2AR antagonists with the potential for design of new atypical antipsychotics
Some important atypical antipsychotic drugs target the serotonergic receptor 2A (5-HT2AR). Currently, new therapeutic strategies are needed to offer faster onset of action with fewer side effects and, therefore, greater efficacy in a substantial proportion of patients with neuropsychological disorders such as Autism and Parkinson. The main objective of this work was to use SBDD methods to identify new hit compounds potentially useful as precursors of novel and selective 5-HT2AR antagonists. A structure-based pharmacophore screening study based on a selective antagonist was carried out in ten databases. The set obtained was refined using molecular docking, and the five most promising compounds were subjected to molecular dynamics simulations. The most stable and promising hit occupied a side pocket present in the 5-HT2AR, a site that can be explored to obtain selective ligands. Simulations against 5-HT2CR and D2R showed that the best hit could not form stable complexes with these targets, strengthening the hypothesis that the hit presents selective binding by the receptor of interest. The selected hits showed some predicted toxicity risk or violated some drug-likeness property. However, it can be concluded that the identified hits are the most promising for performing in vitro assays. Once the presence of activity is confirmed, they could become precursors of optimized and selective antagonists of 5-HT2AR. Graphical abstract An SBDD study was carried out to identify new selective 5-HT2AR ligands potentially useful for designing selective atypical antipsychotics.
- 21 November 2022
- Published by Springer Nature in Molecular Diversity
- Vol. 27 (5) , 2217-2238
Pharmacophore modeling, molecular docking, and molecular dynamics studies to identify new 5-HT2AR antagonists with the potential for design of new atypical antipsychotics
Some important atypical antipsychotic drugs target the serotonergic receptor 2A (5-HT2AR). Currently, new therapeutic strategies are needed to offer faster onset of action with fewer side effects and, therefore, greater efficacy in a substantial proportion of patients with neuropsychological disorders such as Autism and Parkinson. The main objective of this work was to use SBDD methods to identify new hit compounds potentially useful as precursors of novel and selective 5-HT2AR antagonists. A structure-based pharmacophore screening study based on a selective antagonist was carried out in ten databases. The set obtained was refined using molecular docking, and the five most promising compounds were subjected to molecular dynamics simulations. The most stable and promising hit occupied a side pocket present in the 5-HT2AR, a site that can be explored to obtain selective ligands. Simulations against 5-HT2CR and D2R showed that the best hit could not form stable complexes with these targets, strengthening the hypothesis that the hit presents selective binding by the receptor of interest. The selected hits showed some predicted toxicity risk or violated some drug-likeness property. However, it can be concluded that the identified hits are the most promising for performing in vitro assays. Once the presence of activity is confirmed, they could become precursors of optimized and selective antagonists of 5-HT2AR. Graphical abstract An SBDD study was carried out to identify new selective 5-HT2AR ligands potentially useful for designing selective atypical antipsychotics.